Recent content from Joe Carlson
FDA issues warning, but patch reportedly ready.
The market will be watching closely to see if the two companies — which combined last week — can drive investment in the next technological breakthrough while managing high debt, working several other pending deals and melding differences in their corporate cultures.
Focus turns on integration teams from both companies that continue to work on the transition.
$25 billion deal is expected to become profitable for Abbott in the first year.
If you want to prevent computer hackers from attacking medical devices, it's not enough to just design the best device you can before shipping it out the door.
The closing follows months of regulatory review that required the companies to divest several proprietary devices.
Medtronic was dealt a legal setback Wednesday when a federal appeals court reinstated litigation from investment funds claiming that the medical device company misled investors…
Roseville's EnteroMedics thinks a new study will help its case with insurers.
New product can treat atrial fibrillation more quickly.
Maker of SleepSack will still use brand to market.
A "simple" plastic cap made in Maple Grove could reduce the infection rate for patients.
Outside contractor hired to replace Columbia Heights jobs.
The picture presented at a University of Minnesota event was of two scientific communities running in tandem: One is run by and for patients, focused on their immediate needs, while the other is comprised of big companies and research groups.
The pact with University Hospitals Cleveland medical Center is Medtronic's first integrated health solutions agreement in the U.S.
The company said it believes sales woes will be temporary as new products drive a recovery.
Boston is paying $210 million cash for the company, and says it's evaluating strategic options for one of EndoChoice's key products.
Maple Grove's Inspire Medical Systems uses an electric stimulator similar to a pacemaker to treat sleep apnea and snoring.
Omar Ishrak is among the leaders who assured employees of commitment to core values.
The FDA is grappling with how far companies can go in touting uses that haven't been studied.
They want freer exchanges on unapproved uses; critics are leery.
Physician says that research is decreasing due to regulations.
The Patient Safety Movement Foundation was founded four years ago by Masimo CEO Joe Kiani.
Although St. Jude had fixed the problem in 2015 that led to a recall of the devices, the company kept selling its stock of older units.
A clinical trial has yet to show that its Synergy stent outperforms cheaper rivals, but device maker insists time will tell
The latest deaths follow more than a dozen problems with the implanted SynchroMed II.
Seven reports of lost telemetry and pacing output have been reported from the device maker's Nanostim leadless pacemaker.
The company said its medical-surgical group paced sales growth in the third quarter.
Filings in cybersecurity lawsuit come just before shareholders vote on the sale to Abbott.
The agency wants examples of what the rules should be regarding medical products.
Sales of pacemakers and defibrillators fell, but overall revenue surged.
New thinking helps health firms control always-rising expenses.
Agency says it wants to work with firms if hackers target medical hardware.
"Physicians might change their minds if they knew how many problems there really were," said a former FDA official who left the agency to found a search engine that tracks device performance.
Minneapolis medical conference will address why men and women are treated differently for heart attacks
Med-tech conference will look at treatment disparities for the sexes.
As health care costs soar, industry will seek solutions.
Analysts see limited impact to revenue despite lingering questions.
Minnesota-based St. Jude Medical said today that nearly 350,000 defibrillators implanted in patients may be prone to short-circuiting in a way that causes the device to fail unexpectedly. Two deaths have been associated with the devices failing.
Bryan C. Szweda, who was an executive at St. Jude Medical before being charged last year with embezzling $140,000, wants to pry open his former…
The company said extra material might have been left inside some devices.
Shareholders say their tax hit was unfair, but the company argues state law doesn't allow them to pursue their case.
The three firms that made the seven devices haven't been identified, so the implications for Minnesota firms are not clear.
Med-tech pioneer Manny Villafaña is continuing his quest for a blood vessel that could revolutionize coronary bypass surgery
Problems with the HVAD pump can happen when moisture interacts with its electronic components.
The latest version of the firm's MiniMed unit can learn, react to a patient's personal needs.
U team hopes device can replace defective arteries, eliminating the need for multiple surgeries.
The Georgia company reported sales of $72.3 million in 2015, up 18 percent from the previous year.
Patients would like units that don't need to be replaced as often, but a greater cost and size limit their value to manufacturers.
The market for robotic systems used in surgeries is expected to grow rapidly in coming years.
It alleges a short-seller and partners drove down stock with false claims.
A report saying its devices lacked needed safeguards has so far proved untrue.
Recent claims about hackers being able to remotely shut down pacemakers and defibrillators from St. Jude Medical don't appear supported by evidence offered so far, an independent analysis has found.
Muddy Waters raised the ante in its bid to devalue St. Jude's stock.
Trading of the company's stock was briefly halted Friday afternoon.
Officials said company should see quick benefit from recent acquisition of HeartWare.
A short seller says half of the company's revenue could be at stake; St. Jude said the claims are untrue.
Security experts meeting in Minneapolis this week want to help firms fend off cybercrimes.
The Minnesota-run company informed doctors that it is voluntarily updating its instructions for using the minimally invasive EnVeo R delivery system.
The medical device company's new CEO has been chairman of its board of directors for nearly two years.
Roy Almen held his wife Shirley’s hand as she died, surrounded by family, in their home in Brooklyn Park. Two days later the same family…
Execs could have millions in taxes covered if they leave in wake of Abbott deal.
Recall follows three deaths and affects older valve systems not yet implanted in patients.
The revolutionary device does not require open-heart surgery.
Four years since hitting its nadir, Boston Scientific looks like a company on the move.
It raised its financial outlook for 2016 with rising sales, but one-time writedowns contributed to a loss for the quarter.
Its largest division has already taken a hit, and the complexity of a merger hasn't started yet.
Just days before trial, medical device maker Boston Scientific Corp. has agreed to pay the Internal Revenue Service $275 million plus interest to settle more…
Regulators want a closer look, but the two expect it finalized by year's end.
Move comes as Mazor Robotics is set to announce a new guidance system.
Franken had asked it questions about late Medtronic report.
It will pay $600,000 for allegedly missing deadlines to report price information.
The company faces more than 36,000 product liability cases related to the devices.
A judge sided with the company in a yearslong dispute with the IRS.
Lewis Pell's proxy challenge prevailed and now shareholders wonder about the next chapter.
The company said a trial with a new insulin pump showed progress in controlling glucose levels.
Senators press Justice Dept. on its prosecution of Vascular Solutions.
More from Star Tribune